Cargando…

Novel Potential Biomarkers for Retinopathy of Prematurity

Retinopathy of prematurity (ROP) is the main risk factor for vision-threatening disease in premature infants with low birth weight. An accumulating number of independent studies have focused on ROP pathogenesis and have demonstrated that laser photocoagulation therapy and/or anti-VEGF treatment are...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Wei, Li, Bingyan, Wang, Zicong, Zou, Jingling, Jia, Yang, Yoshida, Shigeo, Zhou, Yedi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848752/
https://www.ncbi.nlm.nih.gov/pubmed/35187013
http://dx.doi.org/10.3389/fmed.2022.840030
_version_ 1784652322459090944
author Tan, Wei
Li, Bingyan
Wang, Zicong
Zou, Jingling
Jia, Yang
Yoshida, Shigeo
Zhou, Yedi
author_facet Tan, Wei
Li, Bingyan
Wang, Zicong
Zou, Jingling
Jia, Yang
Yoshida, Shigeo
Zhou, Yedi
author_sort Tan, Wei
collection PubMed
description Retinopathy of prematurity (ROP) is the main risk factor for vision-threatening disease in premature infants with low birth weight. An accumulating number of independent studies have focused on ROP pathogenesis and have demonstrated that laser photocoagulation therapy and/or anti-VEGF treatment are effective. However, early diagnosis of ROP is still critical. At present, the main method of ROP screening is based on binocular indirect ophthalmoscopy. However, the judgment of whether ROP occurs and whether treatment is necessary depends largely on ophthalmologists with a great deal of experience. Therefore, it is essential to develop a simple, accurate and effective diagnostic method. This review describes recent findings on novel biomarkers for the prediction, diagnosis and prognosis of ROP patients. The novel biomarkers were separated into the following categories: metabolites, cytokines and growth factors, non-coding RNAs, iconography, gut microbiota, oxidative stress biomarkers, and others. Biomarkers with high sensitivity and specificity are urgently needed for the clinical applications of ROP. In addition, using non-invasive or minimally invasive methods to obtain samples is also important. Our review provides an overview of potential biomarkers of ROP.
format Online
Article
Text
id pubmed-8848752
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88487522022-02-17 Novel Potential Biomarkers for Retinopathy of Prematurity Tan, Wei Li, Bingyan Wang, Zicong Zou, Jingling Jia, Yang Yoshida, Shigeo Zhou, Yedi Front Med (Lausanne) Medicine Retinopathy of prematurity (ROP) is the main risk factor for vision-threatening disease in premature infants with low birth weight. An accumulating number of independent studies have focused on ROP pathogenesis and have demonstrated that laser photocoagulation therapy and/or anti-VEGF treatment are effective. However, early diagnosis of ROP is still critical. At present, the main method of ROP screening is based on binocular indirect ophthalmoscopy. However, the judgment of whether ROP occurs and whether treatment is necessary depends largely on ophthalmologists with a great deal of experience. Therefore, it is essential to develop a simple, accurate and effective diagnostic method. This review describes recent findings on novel biomarkers for the prediction, diagnosis and prognosis of ROP patients. The novel biomarkers were separated into the following categories: metabolites, cytokines and growth factors, non-coding RNAs, iconography, gut microbiota, oxidative stress biomarkers, and others. Biomarkers with high sensitivity and specificity are urgently needed for the clinical applications of ROP. In addition, using non-invasive or minimally invasive methods to obtain samples is also important. Our review provides an overview of potential biomarkers of ROP. Frontiers Media S.A. 2022-02-02 /pmc/articles/PMC8848752/ /pubmed/35187013 http://dx.doi.org/10.3389/fmed.2022.840030 Text en Copyright © 2022 Tan, Li, Wang, Zou, Jia, Yoshida and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Tan, Wei
Li, Bingyan
Wang, Zicong
Zou, Jingling
Jia, Yang
Yoshida, Shigeo
Zhou, Yedi
Novel Potential Biomarkers for Retinopathy of Prematurity
title Novel Potential Biomarkers for Retinopathy of Prematurity
title_full Novel Potential Biomarkers for Retinopathy of Prematurity
title_fullStr Novel Potential Biomarkers for Retinopathy of Prematurity
title_full_unstemmed Novel Potential Biomarkers for Retinopathy of Prematurity
title_short Novel Potential Biomarkers for Retinopathy of Prematurity
title_sort novel potential biomarkers for retinopathy of prematurity
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848752/
https://www.ncbi.nlm.nih.gov/pubmed/35187013
http://dx.doi.org/10.3389/fmed.2022.840030
work_keys_str_mv AT tanwei novelpotentialbiomarkersforretinopathyofprematurity
AT libingyan novelpotentialbiomarkersforretinopathyofprematurity
AT wangzicong novelpotentialbiomarkersforretinopathyofprematurity
AT zoujingling novelpotentialbiomarkersforretinopathyofprematurity
AT jiayang novelpotentialbiomarkersforretinopathyofprematurity
AT yoshidashigeo novelpotentialbiomarkersforretinopathyofprematurity
AT zhouyedi novelpotentialbiomarkersforretinopathyofprematurity